News & Events - Viking Therapeutics InvestorRoom
Feb 27, 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity. Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo.
Viking Therapeutics Reports New Data from VK2735 Obesity …
Nov 4, 2024 · Mild nausea was reported in 23 (32%) VK2735-treated subjects compared with 11% among placebo subjects. No moderate or severe nausea was reported. Vomiting was reported in three (4%) VK2735-treated subjects. Diarrhea was reported in five subjects (7%) receiving VK2735 compared with four subjects (21%) receiving placebo.
News & Events - Viking Therapeutics InvestorRoom
Mar 26, 2024 · The 28-day MAD study results highlight positive signs of clinical activity following treatment with oral VK2735. Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 3.3%.
Viking Therapeutics Announces Positive Top-Line Results from …
Feb 27, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Viking Therapeutics Announces Results from Phase 1 Clinical Trial …
Mar 26, 2024 · The 28-day MAD study results highlight positive signs of clinical activity following treatment with oral VK2735. Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body...
Viking Therapeutics Announces Completion of Enrollment in …
Oct 23, 2023 · The VENTURE trial will evaluate weekly VK2735 doses of up to 15 mg, compared to the 10 mg top dose evaluated in the prior Phase 1 multiple ascending dose (MAD) study.
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial …
Oct 17, 2023 · Data from a Phase 1 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical...
Viking Therapeutics Stock Climbs On Positive Data From VK2735 …
Nov 4, 2024 · The company added that persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3 percent from baseline, four weeks after the last dose of VK2735 was ...
VK2735 - Viking Therapeutics
The 28-day MAD study results highlight positive signs of clinical activity following treatment with oral VK2735. Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%. Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative to placebo, ranging up to 3.3%.
Viking to Accelerate Development of Obesity Drug With Two Q4
Oct 24, 2024 · Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II trial for an oral formulation.